Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Azithromycin Phenotypic versus Clinical Resistance.

Literature DB >> 31862771

Azithromycin Phenotypic versus Clinical Resistance.

Paul H Edelstein^1,2.

Abstract

Entities: Chemical

Keywords: Legionella pneumophilazzm321990; azithromycin; epidemiologic cutoff value

Mesh：

Substances：
Azithromycin

Year: 2019 PMID： 31862771 PMCID： PMC7187571 DOI： 10.1128/AAC.01986-19

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

× No keyword cloud information.

7 in total

1. Antibiotic Resistance and Azithromycin Resistance Mechanism of Legionella pneumophila Serogroup 1 in China.

Authors: Xueyang Jia; Hongyu Ren; Xudong Nie; Yinan Li; Jianguo Li; Tian Qin
Journal: Antimicrob Agents Chemother Date: 2019-09-23 Impact factor: 5.191

2. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses.

Authors: K M Olsen; G San Pedro; L P Gann; P O Gubbins; D M Halinski; G D Campbell
Journal: Antimicrob Agents Chemother Date: 1996-11 Impact factor: 5.191

Review 3. Azithromycin--review of key chemical, pharmacokinetic and microbiological features.

Authors: H Lode; K Borner; P Koeppe; T Schaberg
Journal: J Antimicrob Chemother Date: 1996-06 Impact factor: 5.790

4. Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages.

Authors: D A Stamler; M A Edelstein; P H Edelstein
Journal: Antimicrob Agents Chemother Date: 1994-02 Impact factor: 5.191

5. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.

Authors: Keith A Rodvold; Larry H Danziger; Mark H Gotfried
Journal: Antimicrob Agents Chemother Date: 2003-08 Impact factor: 5.191

6. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia.

Authors: Shigeru Kohno; Kazuhiro Tateda; Jun-ichi Kadota; Jiro Fujita; Yoshihito Niki; Akira Watanabe; Masahito Nagashima
Journal: J Infect Chemother Date: 2013-12-11 Impact factor: 2.211

7. Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin.

Authors: M Lucchi; B Damle; A Fang; P J de Caprariis; A Mussi; S P Sanchez; G Pasqualetti; M Del Tacca
Journal: J Antimicrob Chemother Date: 2008-02-04 Impact factor: 5.790

7 in total

3 in total